Dr. Klegerman received a B.A. in chemistry from the University of Illinois at Chicago in 1968 and a Ph.D. in biochemistry from Loyola University of Chicago in 1984.
For more than 30 years, he has conducted biomedical research focusing on immunochemistry, immunoassay development, and conjugation chemistry. For the past 25 years, Dr. Klegerman has been involved in a collaborative effort with cardiovascular researchers under the direction of Dr. David D. McPherson to develop targeted immunoliposomes for diagnosis and treatment of cardiovascular diseases, joining the group when they moved to The University of Texas Health Science Center in Houston, where he now is an associate professor in the Division of Cardiovascular Diseases. As part of this effort, Dr. Klegerman founded two companies to develop the echogenic liposome technology into clinical products.
He is an author of 79 scientific papers, awardee of four patents, and co-editor of a textbook of pharmaceutical biotechnology (1992).